Peer-influenced content. Sources you trust. No registration required. This is HCN.
Practical Neurology
HyQvia, now FDA-approved for CIDP, shows a significant reduction in relapse rates, presenting an effective subcutaneous alternative to IVIG infusions.
Neurology January 23rd 2024
Hemophilia News Today
Roctavian represents a turning point in hemophilia A management, offering patients like Maxwell a potential lifetime of relief from traditional therapies. This gene therapy directly targets the genetic cause, paving the way for innovative treatments in genetic disorders.
Hematology January 22nd 2024
Medical Professionals Reference (MPR)
Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.
Hematology/Oncology January 22nd 2024
Oncology News Central (ONC)
In a major stride for cervical cancer treatment, the FDA-approved pembrolizumab in combination with CRT demonstrates significant improvement in progression-free survival for FIGO 2014 stage III-IVA patients, marking a pivotal change in therapeutic approaches.
CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.
Hematology/Oncology January 16th 2024
An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.
Oncology, Medical January 8th 2024